Chemed (CHE) CFO granted 19,486 stock options at $443.79
Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Chemed Corp (CHE) reported a Form 4 for VP & Chief Financial Officer Michael D. Witzeman, showing a grant of 19,486 stock options on 10/21/2025. Each option has an exercise price of $443.79 and is a right to buy capital stock, expiring on 10/21/2030.
The award vests in three equal annual installments commencing 10/21/2026. Following this transaction, the reporting person beneficially owned 53,970 derivative securities, held in Direct ownership form.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy with tandem tax withholding) | 19,486 | $443.79 | $8.65M |
Footnotes (1)
- F1. Vesting in three equal annual installments commencing 10/21/2026
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CHE disclose in this Form 4?
How many options were granted and at what exercise price for CHE?
What is the vesting schedule for the CHE CFO’s options?
When do the reported CHE options expire?
How many derivative securities does the filer own after the transaction?
What is the ownership form of the reported securities?
Who is the reporting person in CHE’s Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.